Henry Po-Hung Lin

US Patent:

6558708, May 6, 2003

Filed:

Apr 10, 2000

Appl. No.:

09/546119

Inventors:

Henry C. Lin - Manhattan Beach CA

Assignee:

Cedars-Sinai Medical Center - Los Angeles CA

International Classification:

A61K 916

US Classification:

424490, 424451, 424464, 424474, 424489

Abstract:

Disclosed are a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging the residence time of an orally or enterally administered substance by promoting its dissolution, bioavailability and/or absorption in the small intestine is also described. These methods are related to a method of transmitting to and replicating at a second location in the central nervous system a serotonergic neural signal originating at a first location in the proximal or distal gut of a mammal and/or a method of transmitting to and replicating at a second location in the upper gastrointestinal tract a serotonergic neural signal originating at a first location in the proximal or distal gut.

US Patent:

6562629, May 13, 2003

Filed:

Aug 11, 1999

Appl. No.:

09/374143

Inventors:

Henry C. Lin - Manhattan Beach CA
Mark Pimentel - Los Angeles CA

Assignee:

Cedars-Sinai Medical Center - Los Angeles CA

International Classification:

G01N 33564

US Classification:

436506, 435 4, 435 71

Abstract:

Disclosed is a method of diagnosing small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder (ADHD), or an autoimmune disease by sampling serum from a human subject having a suspected diagnosis of any of these conditions and analyzing the serum for the presence of ASCA, which corroborates the suspected diagnosis. A method of determining a predisposition for developing Crohns, in a human subject who does not present a set of symptoms characteristic of the disease and who has small intestinal bacterial overgrowth, involves sampling serum from the subject and analyzing the serum for the presence of ASCA. The presence of ASCA in the serum indicates a predisposition for developing Crohns disease. Also disclosed is a kit for diagnosing and treating small intestinal bacterial overgrowth, irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, or an autoimmune disease, such as multiple sclerosis or systemic lupus erythematosus.

US Patent:

6805852, Oct 19, 2004

Filed:

Mar 26, 2002

Appl. No.:

10/107240

Inventors:

Henry C. Lin - Manhattan Beach CA
Mark Pimentel - Los Angeles CA

Assignee:

Cedars-Sinai Medical Center - Los Angeles CA

International Classification:

A61K 5100

US Classification:

424 111, 424 91, 435 4, 435 772, 435 34

Abstract:

Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohns disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, or Crohns disease.

US Patent:

6861053, Mar 1, 2005

Filed:

Aug 11, 1999

Appl. No.:

09/374142

Inventors:

Henry C. Lin - Manhattan Beach CA, US
Mark Pimentel - Los Angeles CA, US

Assignee:

Cedars-Sinai Medical Center - Los Angeles CA

International Classification:

A01N063/00
A01N065/00
A01N037/18
A61K035/00
A61K039/00

US Classification:

424 931, 424 934, 424 9345, 424114, 424116, 4241841, 514 2

Abstract:

Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, or Crohn's disease.

US Patent:

7048906, May 23, 2006

Filed:

Apr 17, 2001

Appl. No.:

09/837797

Inventors:

Henry C. Lin - Manhattan Beach CA, US
Mark Pimentel - Los Angeles CA, US

Assignee:

Cedars-Sinai Medical Center - Los Angeles CA

International Classification:

A61K 49/00
A61K 39/00
A61K 35/00
A01K 63/00

US Classification:

424 92, 424 91, 424116, 4242781, 424439, 426 2, 426 71, 426658, 426800, 426801, 435 4, 435 29

Abstract:

Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.

US Patent:

7056686, Jun 6, 2006

Filed:

Aug 10, 2004

Appl. No.:

10/915193

Inventors:

Henry C. Lin - Manhattan Beach CA, US
Mark Pimentel - Los Angeles CA, US

Assignee:

Cedars-Sinai Medical Center - Los Angeles CA

International Classification:

G01N 33/53
G01N 23/00
G01N 33/50
G01N 33/564

US Classification:

435 71, 436 57, 436 68, 436506

Abstract:

Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, or Crohn's disease.

US Patent:

7081239, Jul 25, 2006

Filed:

Mar 26, 2004

Appl. No.:

10/810020

Inventors:

Henry C. Lin - Manhattan Beach CA, US

Assignee:

Cedars-Sinai Medical Center Burns and Allen Research Center - Los Angeles CA

International Classification:

A61K 49/00
A61K 39/00
A61K 35/00
A61K 63/00

US Classification:

424 92, 424 91, 424116, 4242781, 424439, 426 2, 426 71, 426658, 426800, 426801, 435 4, 435 29

Abstract:

Disclosed is a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging the residence time of an orally or enterally administered substance by promoting its dissolution, bioavailability and/or absorption in the small intestine is also described. These methods are related to a method of transmitting to and replicating at a second location in the central nervous system a serotonergic neural signal originating at a first location in the proximal or distal gut of a mammal and/or a method of transmitting to and replicating at a second location in the upper gastrointestinal tract a serotonergic neural signal originating at a first location in the proximal or distal gut.

US Patent:

7244412, Jul 17, 2007

Filed:

May 26, 2004

Appl. No.:

10/853824

Inventors:

Henry C. Lin - Manhattan Beach CA, US

Assignee:

Cedars-Sinai Medical Center - Los Angeles CA

International Classification:

A61K 49/00
A61K 39/00
A61K 35/00
A61K 63/00

US Classification:

424 92, 424 91, 424116, 4242781, 424439, 426 2, 426 71, 426658, 426800, 426801, 435 4, 435 29

Abstract:

Disclosed is a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging the residence time of an orally or enterally administered substance by promoting its dissolution, bioavailability and/or absorption in the small intestine is also described. These methods are related to a method of transmitting to and replicating at a second location in the central nervous system a serotonergic neural signal originating at a first location in the proximal or distal gut of a mammal and/or a method of transmitting to and replicating at a second location in the upper gastrointestinal tract a serotonergic neural signal originating at a first location in the proximal or distal gut.